Author

Gene G. Olinger

Adjunct Professor Medicine, Boston University - Cited by 10,612 - Virology

Biography

Gene G Olinger currently works for MRIGlobal in the Global Health Division. Gene does research in Microbiology, Immunology and Virology. Author's most of the publications are done in the field of Vaccination, virus diseases, study of virus, microbiology, immunology and molecular virology.
Title
Cited by
Year
Evaluation of candidate vaccine approaches for MERS-CoV
L Wang, W Shi, MG Joyce, K Modjarrad, Y Zhang, K Leung, CR Lees, ...Nature communications 6 (1), 7712, 2015201
305
2015
A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity
LM Johansen, LE DeWald, CJ Shoemaker, BG Hoffstrom, ...Science translational medicine 7 (290), 290ra89-290ra89, 2015201
252
2015
Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study
DV Clark, H Kibuuka, M Millard, S Wakabi, L Lukwago, A Taylor, MA Eller, ...The Lancet Infectious Diseases 15 (8), 905-912, 2015201
247
2015
Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies
J Dyall, R Gross, J Kindrachuk, RF Johnson, GG Olinger Jr, LE Hensley, ...Drugs 77 (18), 1935-1966, 2017201
203
2017
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
T Luke, H Wu, J Zhao, R Channappanavar, CM Coleman, JA Jiao, ...Science translational medicine 8 (326), 326ra21-326ra21, 2016201
115
2016
Inhibition of Ebola and Marburg virus entry by G protein-coupled receptor antagonists
H Cheng, CM Lear-Rooney, L Johansen, E Varhegyi, ZW Chen, ...Journal of virology 89 (19), 9932-9938, 2015201
110
2015
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection
EA Nelson, J Dyall, T Hoenen, AB Barnes, H Zhou, JY Liang, J Michelotti, ...PLoS neglected tropical diseases 11 (4), e0005540, 2017201
94
2017
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
RF Johnson, U Bagci, L Keith, X Tang, DJ Mollura, L Zeitlin, J Qin, ...Virology 490, 49-58, 2016201
78
2016
Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail
JR Kugelman, J Kugelman-Tonos, JT Ladner, J Pettit, CM Keeton, ...Cell reports 12 (12), 2111-2120, 2015201
75
2015
Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
M Meyer, T Garron, NM Lubaki, CE Mire, KA Fenton, C Klages, ...The Journal of clinical investigation 125 (8), 3241-3255, 2015201
71
2015
MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses
A Bruchez, K Sha, J Johnson, L Chen, C Stefani, H McConnell, ...Science 370 (6513), 241-247, 2020202
71
2020
Viral hemorrhagic fever diagnostics
LD Racsa, CS Kraft, GG Olinger, LE HensleyClinical Infectious Diseases 62 (2), 214-219, 2016201
68
2016
Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures
J Dyall, EA Nelson, LE DeWald, R Guha, H Zhou, E Postnikova, J Logue, ...The Journal of infectious diseases 218 (suppl_5), S672-S678, 2018201
55
2018
The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus
LK McMullan, M Flint, J Dyall, C Albariño, GG Olinger, S Foster, P Sethna, ...Antiviral research 125, 71-78, 2016201
53
2016
Antibody therapeutics for Ebola virus disease
L Zeitlin, KJ Whaley, GG Olinger, M Jacobs, R Gopal, X Qiu, GP KobingerCurrent opinion in virology 17, 45-49, 2016201
52
2016
Project IDentif. AI: harnessing artificial intelligence to rapidly optimize combination therapy development for infectious disease intervention
A Abdulla, B Wang, F Qian, T Kee, A Blasiak, YH Ong, L Hooi, F Parekh, ...Advanced therapeutics 3 (7), 2000034, 2020202
46
2020
Protective mAbs and cross-reactive mAbs raised by immunization with engineered Marburg virus GPs
ML Fusco, T Hashiguchi, R Cassan, JE Biggins, CD Murin, KL Warfield, ...PLoS pathogens 11 (6), e1005016, 2015201
44
2015
Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs
E Postnikova, Y Cong, LE DeWald, J Dyall, S Yu, H Zhou, R Gross, ...PLoS One 13 (3), e0194880, 2018201
43
2018
Inhibition of Ebola virus by a molecularly engineered banana lectin
EM Covés-Datson, J Dyall, LE DeWald, SR King, D Dube, M Legendre, ...PLoS neglected tropical diseases 13 (7), e0007595, 2019201
42
2019
Nonhuman primate models of Ebola virus disease
RS Bennett, LM Huzella, PB Jahrling, L Bollinger, GG Olinger, LE HensleyMarburg-and Ebolaviruses: From Ecosystems to Molecules, 171-193, 2017201
42
2017

Referred From: https://scholar.google.com/citations?hl=en&user=eTmGhcQAAAAJ

Cited by
Citations 10612
h-index 55
i10-index 93
Recommended Journals
Open Access Journals